APA (7th ed.) Citation

Yang, S., Hou, Y., Wang, X., Kang, S., & Pan, Z. (2026). Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLoS ONE, 21(6), 1. https://doi.org/10.1371/journal.pone.0351029

Chicago Style (17th ed.) Citation

Yang, Shuo, Yibing Hou, Xiaohui Wang, Shuo Kang, and Zhenhua Pan. "Economic Evaluation of Atezolizumab in Combination with Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer in China: A Cost-effectiveness Analysis." PLoS ONE 21, no. 6 (2026): 1. https://doi.org/10.1371/journal.pone.0351029.

MLA (9th ed.) Citation

Yang, Shuo, et al. "Economic Evaluation of Atezolizumab in Combination with Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer in China: A Cost-effectiveness Analysis." PLoS ONE, vol. 21, no. 6, 2026, p. 1, https://doi.org/10.1371/journal.pone.0351029.